Market Overview

UPDATE: Jefferies Downgrades Infinity Pharmaceuticals to Hold on Limited Upside

Related INFI
Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

Jefferies reduced its rating on Infinity Pharmaceuticals (NASDAQ: INFI) from Buy to Hold but raised its price target from $18 to $21.

Jefferies noted, "In the absence of positive events, INFI has gained significant traction on increased visibility of IPI-145 in Ph1/2a (its achievable potential yet-to-be defined; YTD +130% vs. +30% for NBI). While biotech valuation is often based on perceived potential for early-stage assets, at EV of ~$470M (vs. ~$490M for peers), with limited clinical data and numerous competitors in development, we view a Hold rating as appropriate for INFI.."

Infinity Pharmaceuticals closed at $20.20 on Tuesday.

Latest Ratings for INFI

DateFirmActionFromTo
Dec 2014Credit SuisseUpgradesNeutralOutperform
Nov 2014NomuraMaintainsNeutral
Oct 2014Stifel NicolausInitiates Coverage onHold

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters